Skip to content
TrialScanner

NCT05442190

Topical SGX302 for Mild-to-Moderate Psoriasis

Phase 2CompletedSNGXLead

Registry record

Lead sponsor
Soligenix
Conditions
Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris
Primary completion
Oct 22, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05442190 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.